203 related articles for article (PubMed ID: 25870378)
1. Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes.
de la Morena Barrio P; Conesa MÁ; González-Billalabeitia E; Urrego E; García-Garre E; García-Martínez E; Poves MZ; Vicente V; de la Peña FA
J Natl Compr Canc Netw; 2015 Apr; 13(4):417-23. PubMed ID: 25870378
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
Ghoreishi Z; Keshavarz S; Asghari Jafarabadi M; Fathifar Z; Goodman KA; Esfahani A
BMC Cancer; 2018 Oct; 18(1):958. PubMed ID: 30290775
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of paclitaxel-induced peripheral neuropathy in patients using clopidogrel: a retrospective pilot study.
Matsuo M; Ito H; Takemura Y; Hattori M; Kawakami M; Takahashi N; Yamazaki M
J Anesth; 2017 Aug; 31(4):631-635. PubMed ID: 28451807
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Tanabe Y; Shimizu C; Hamada A; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yamamoto H; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1179-1186. PubMed ID: 28447211
[TBL] [Abstract][Full Text] [Related]
6. Estrogen decline is a risk factor for paclitaxel-induced peripheral neuropathy: Clinical evidence supported by a preclinical study.
Miyamoto T; Hiramoto S; Kanto A; Tsubota M; Fujitani M; Fukuyama H; Hatanaka S; Sekiguchi F; Koizumi Y; Kawabata A
J Pharmacol Sci; 2021 May; 146(1):49-57. PubMed ID: 33858655
[TBL] [Abstract][Full Text] [Related]
7. Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer.
Kanbayashi Y; Hosokawa T; Kitawaki J; Taguchi T
Anticancer Res; 2013 Mar; 33(3):1153-6. PubMed ID: 23482795
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.
Tanabe Y; Hashimoto K; Shimizu C; Hirakawa A; Harano K; Yunokawa M; Yonemori K; Katsumata N; Tamura K; Ando M; Kinoshita T; Fujiwara Y
Int J Clin Oncol; 2013 Feb; 18(1):132-8. PubMed ID: 22105895
[TBL] [Abstract][Full Text] [Related]
9. Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors.
Kober KM; Olshen A; Conley YP; Schumacher M; Topp K; Smoot B; Mazor M; Chesney M; Hammer M; Paul SM; Levine JD; Miaskowski C
Mol Pain; 2018; 14():1744806918816462. PubMed ID: 30426838
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial.
Ghoreishi Z; Esfahani A; Djazayeri A; Djalali M; Golestan B; Ayromlou H; Hashemzade S; Asghari Jafarabadi M; Montazeri V; Keshavarz SA; Darabi M
BMC Cancer; 2012 Aug; 12():355. PubMed ID: 22894640
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors.
Kober KM; Mazor M; Abrams G; Olshen A; Conley YP; Hammer M; Schumacher M; Chesney M; Smoot B; Mastick J; Paul SM; Levine JD; Miaskowski C
J Pain Symptom Manage; 2018 Dec; 56(6):908-919.e3. PubMed ID: 30172061
[TBL] [Abstract][Full Text] [Related]
12. Perturbations in neuroinflammatory pathways are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors.
Miaskowski C; Topp K; Conley YP; Paul SM; Melisko M; Schumacher M; Chesney M; Abrams G; Levine JD; Kober KM
J Neuroimmunol; 2019 Oct; 335():577019. PubMed ID: 31401418
[TBL] [Abstract][Full Text] [Related]
13. Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors: A retrospective study in Japan.
Hiramoto S; Asano H; Miyamoto T; Takegami M; Kawabata A
PLoS One; 2021; 16(12):e0261473. PubMed ID: 34972132
[TBL] [Abstract][Full Text] [Related]
14.
Abdelfattah NM; Solayman MH; Elnahass Y; Sabri NA
Genet Test Mol Biomarkers; 2021 Jul; 25(7):471-477. PubMed ID: 34280009
[No Abstract] [Full Text] [Related]
15. Activation of KCNQ Channels Prevents Paclitaxel-Induced Peripheral Neuropathy and Associated Neuropathic Pain.
Li L; Li J; Zuo Y; Dang D; Frost JA; Yang Q
J Pain; 2019 May; 20(5):528-539. PubMed ID: 30471428
[TBL] [Abstract][Full Text] [Related]
16. Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients.
Karteri S; Bruna J; Argyriou AA; Mariotto S; Velasco R; Alemany M; Kalofonou F; Alberti P; Dinoto A; Velissaris D; Stradella A; Cavaletti G; Ferrari S; Kalofonos HP
J Peripher Nerv Syst; 2022 Jun; 27(2):166-174. PubMed ID: 35384143
[TBL] [Abstract][Full Text] [Related]
17. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
Sánchez-Barroso L; Apellaniz-Ruiz M; Gutiérrez-Gutiérrez G; Santos M; Roldán-Romero JM; Curras M; Remacha L; Calsina B; Calvo I; Sereno M; Merino M; García-Donas J; Castelo B; Guerra E; Letón R; Montero-Conde C; Cascón A; Inglada-Pérez L; Robledo M; Rodríguez-Antona C
Oncologist; 2019 Aug; 24(8):e784-e792. PubMed ID: 30470691
[TBL] [Abstract][Full Text] [Related]
18. The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.
Fukada I; Ito Y; Kobayashi K; Shibayama T; Takahashi S; Horii R; Akiyama F; Iwase T; Ohno S
PLoS One; 2017; 12(9):e0184322. PubMed ID: 28898275
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy.
Jennaro TS; Fang F; Kidwell KM; Smith EML; Vangipuram K; Burness ML; Griggs JJ; Van Poznak C; Hayes DF; Henry NL; Hertz DL
Breast Cancer Res Treat; 2020 Apr; 180(3):707-714. PubMed ID: 32166478
[TBL] [Abstract][Full Text] [Related]
20. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
Hertz DL; Roy S; Jack J; Motsinger-Reif AA; Drobish A; Clark LS; Carey LA; Dees EC; McLeod HL
Breast Cancer Res Treat; 2014 May; 145(1):245-54. PubMed ID: 24706167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
